Themis Medicare Faces Significant Volatility Amid Declining Sales and Profit Concerns

Themis Medicare, a small-cap player in the Pharmaceuticals & Drugs industry, has experienced significant volatility today, hitting a new 52-week low of Rs. 118.05. This marks a notable decline of 15.8% from the previous day's close, contributing to a two-day consecutive fall of 18.73%. The stock has underperformed its sector, which has seen a decline of 3.68%, and has lagged behind the broader market, with a one-year performance of -44.58% compared to the Sensex's -2.31%. Key financial metrics reveal a challenging landscape for Themis Medicare. The company reported a sharp decline in net sales, down 10.7% compared to the previous four-quarter average, and a staggering 96.1% drop in profit after tax for the last quarter. Additionally, cash and cash equivalents have reached a low of Rs. 17.60 crore, raising concerns about liquidity. Despite these challenges, Themis Medicare maintains a low debt-to-EBITDA ratio of 1.01, indicating a strong ability to service its debt. The company has also shown healthy long-term growth, with operating profit increasing at an annual rate of 47.04%. However, the stock's technical indicators suggest a bearish trend, reflecting ongoing market pressures.